MedTrace Logo

Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma

NCT01404104 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-07-27

No results posted yet for this study

Summary

Temsirolimus is a drug that is being studied to possibly treat kidney cancer. It works by starving the cancer of nutrients, by cutting off the blood supply, which is hoping to shrink the cancer. This study will look at the experimental use of temsirolimus, 12 weeks prior to the surgical removal of the entire kidney or a portion of the kidney that is involved by the tumor.

Conditions

Interventions

DRUG

Temsirolimus (pre surgery)

Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).

Sponsors & Collaborators

Principal Investigators

  • Anil Kapoor, MD · McMaster Institute of Urology - St. Joseph's Healthcare Hamilton

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01404104 on ClinicalTrials.gov